Premium
Prime–boost bacillus Calmette–Guérin vaccination with lentivirus‐vectored and DNA ‐based vaccines expressing antigens Ag85B and Rv3425 improves protective efficacy against Mycobacterium tuberculosis in mice
Author(s) -
Xu Ying,
Yang Enzhuo,
Wang Jianguang,
Li Rui,
Li Guanghua,
Liu Guoyuan,
Song Na,
Huang Qi,
Kong Cong,
Wang Honghai
Publication year - 2014
Publication title -
immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.297
H-Index - 133
eISSN - 1365-2567
pISSN - 0019-2805
DOI - 10.1111/imm.12308
Subject(s) - vaccination , dna vaccination , antigen , mycobacterium tuberculosis , virology , tuberculosis , immunology , tuberculosis vaccines , immune system , bcg vaccine , viral vector , immunity , biology , cytotoxic t cell , medicine , immunization , recombinant dna , in vitro , gene , biochemistry , pathology
Summary To prevent the global spread of tuberculosis ( TB ), more effective vaccines and vaccination strategies are urgently needed. As a result of the success of bacillus Calmette–Guérin ( BCG ) in protecting children against miliary and meningeal TB , the majority of individuals will have been vaccinated with BCG ; hence, boosting BCG ‐primed immunity will probably be a key component of future vaccine strategies. In this study, we compared the ability of DNA ‐, protein‐ and lentiviral vector‐based vaccines that express the antigens Ag85B and Rv3425 to boost the effects of BCG in the context of immunity and protection against Mycobacterium tuberculosis in C57 BL /6 mice. Our results demonstrated that prime–boost BCG vaccination with a lentiviral vector expressing the antigens Ag85B and Rv3425 significantly enhanced immune responses, including T helper type 1 and CD 8 + cytotoxic T lymphocyte responses, compared with DNA ‐ and protein‐based vaccines. However, lentivirus‐vectored and DNA ‐based vaccines greatly improved the protective efficacy of BCG against M. tuberculosis , as indicated by a lack of weight loss and significantly reduced bacterial loads and histological damage in the lung. Our study suggests that the use of lentiviral or DNA vaccines containing the antigens Ag85B and Rv3425 to boost BCG is a good choice for the rational design of an efficient vaccination strategy against TB .